Subscribe Now Subscribe Today
Science Alert
 
FOLLOW US:     Facebook     Twitter
Blue
   
Curve Top
International Journal of Pharmacology
  Year: 2015 | Volume: 11 | Issue: 5 | Page No.: 405-413
DOI: 10.3923/ijp.2015.405.413
A Review on Salient Pharmacological Features of Momordica charantia
Aparna Upadhyay, Pooja Agrahari and D.K. Singh

Abstract:
Plant Momordica charantia Linn., known as bitter gourd, belongs to family Cucurbitaceae. It is cultivated throughout India, Malaya, China, Tropical Africa and America. Earlier claims showed that its bitter fruits have carminative, aphrodisiac and anthelmintic properties are used in syphilis, rheumatism, troubles of spleen and ophthalmia. It is also useful in piles, leprosy, jaundice and used as a vermifuge. Literature review reveals that the fruit of plant contains moisture (83.2%), proteins (2.9%), fat (1.0%), carbon (9.8%), fibers (1.7%), mineral matters (1.4%), calcium, phosphorus, iron, carotene, thiamine, nicotinic acid, riboflavin, ascorbic acid (88 mg/100 g), copper and potassium. Charantin, β-sitosterol-glucoside, stigmast-5, 25-dien-3 β-O-glucoside, stigmast-7, 25-dien-3 β-ol and stigmast-7, 22, 25-trien-3 β-ol are isolated from the fruit. Many pharmacological properties of M. charantia have been reported, including antioxidant, adipogenesis-reducing, antilipolytic, hypoglycemic, antidiabetic, anticancer, antifertility, anthelmintic, antimicrobial, antiviral and hepatoprotective activity. The present review highlights the salient pharmacological uses of Momordica charantia.
PDF Fulltext XML References Citation Report Citation
 RELATED ARTICLES:
  •    Chemopreventive Potential of Bitter Melon (Momordica charantia) against Precancerous Lesions in the Colon of Fisher 344 Male Rats
  •    Evaluation of Momordica charantia L. Fruit Extract for Analgesic and Anti-inflammatory activities using in vivo Assay
How to cite this article:

Aparna Upadhyay, Pooja Agrahari and D.K. Singh, 2015. A Review on Salient Pharmacological Features of Momordica charantia. International Journal of Pharmacology, 11: 405-413.

DOI: 10.3923/ijp.2015.405.413

URL: https://scialert.net/abstract/?doi=ijp.2015.405.413

 
COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 

       

       

Curve Bottom